FGF21 and metabolic dysfunction-associated steatotic liver disease: Surprisingly, we have not shown a substantial difference in FGF21 levels among subjects with or without NAFLD in our cohort (Table 1), which could possibly be attributed to different stages of liver disease at baseline in patients with NAFLD in this cohort.